Cogent Biosciences, Inc.
15
2
6
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
26.7%
4 terminated/withdrawn out of 15 trials
33.3%
-53.2% vs industry average
7%
1 trials in Phase 3/4
50%
1 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Role: lead
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
Role: lead
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Role: lead
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Role: lead
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Role: lead
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Role: lead
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Role: lead
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Role: lead
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Role: collaborator
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Role: lead
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
Role: lead
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
Role: lead
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
Role: lead
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Role: lead
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
Role: lead
All 15 trials loaded